Finchley HealthCare Ventures Inc. Participates in Capstan Therapeutics Oversubscribed Series B Financing

Capstan Therapeutics Inc., a biotechnology company developing proprietary in vivo cell therapy using targeted lipid nanoparticles, announced on March 20, 2024, the closing of an oversubscribed $175 million financing round. This Series B financing was led by RA Capital Management. New investors included Forbion, Johnson & Johnson Innovation JJDC Inc., Mubadala, Perceptive Advisors, Sofinnova Investments and Finchley Healthcare Ventures Inc., who joined Capstan’s existing investors Alexandria Venture Investments, Bristol Myers Squibb, Eli Lilly and Company, Leaps by Bayer, Novartis Venture Fund, OrbiMed, Pfizer Ventures, Polaris Partners, and Vida Ventures. Proceeds from the financing will be used to advance CPTX2309, Capstan’s lead in vivo chimeric antigen receptor T cell (CAR-T) candidate for autoimmune diseases.

“We are excited to support Capstan’s mission. Their transformative in vivo RNA delivery technology promises to significantly benefit patients by providing a much-needed alternative to complex and risky ex vivo CAR-T cell therapy.” said Pierre Beauparlant, Ph.D., Executive Managing Director of Finchley HealthCare Ventures.

To read Capstan Therapeutics Series B financing Press Release: https://www.capstantx.com/posts/capstan-therapeutics-announces-175m-oversubscribed-series-b-financing/